Tag Archives: Alethia Young

Cantor Fitzgerald Remains a Buy on Biogen Inc (BIIB)

In a report released yesterday, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Biogen Inc (BIIB – Research Report), with a price target of $400. The company’s shares closed yesterday at $322.61. Young commented: “. We reiterate our

Alnylam Pharma (ALNY) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $135. The company’s shares closed yesterday at $79.73. Young commented: “. We reiterate our Overweight rating and

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen Inc (NASDAQ: AMGN), Revance Therapeutics (NASDAQ: RVNC) and AnaptysBio Inc (NASDAQ: ANAB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen Inc (AMGN – Research Report), Revance Therapeutics (RVNC – Research Report) and AnaptysBio Inc (ANAB – Research Report). Amgen Inc (AMGN) Cantor

Cantor Fitzgerald Reiterates a Buy Rating on Intercept Pharma (ICPT)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Intercept Pharma (ICPT – Research Report) today and set a price target of $170. The company’s shares opened today at $104.56. Young observed: “: We reiterate our Overweight rating and

New Buy Rating for Vertex Pharmaceuticals (VRTX), the Healthcare Giant

In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $217. The company’s shares closed yesterday at $167.40. Young wrote: “: $217 PT. Vertex

Sarepta Therapeutics (SRPT) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $217. The company’s shares closed on Friday at $119.35. Young commented: “: Reiterating our Overweight rating and